# A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

> **NCT02846506** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
- **DRUG:** Canagliflozin 50 mg
- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Metformin Extended Release (XR)

## Key facts

- **NCT ID:** NCT02846506
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846506, "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02846506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*